Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136076 | PMC |
| http://dx.doi.org/10.4103/0974-1208.82367 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A retrospective observational clinical study of triple negative breast cancer cases treated with Di Bella Method: A preliminary data.
Neuro Endocrinol Lett
December 2024
Di Bella Foundation, Via Guglielmo Marconi 51 Bologna, 40122 Italy.
Objectives: Triple negative breast cancer (TNBC) is a distinct subtype of breast cancer that has a poor prognosis due to the lack of effective therapeutic agents. Since a significant proportion of human surgical samples of TNBC expressed mRNA for the growth hormone (GH), growth hormone-releasing hormone (GHRH), and gonadotropin-releasing hormone (GnRH) receptors, and the mitogenic proliferative activity of GH, GHRH, and GnRH, have been identified as effective therapeutic targets for somatostatin and its analogs and GnRH analogs, Di Bella Method (DBM), a combination of hormonal analogs and vitamins, was introduced to target and inhibit solid tumors. The present study aimed to improve the prognosis of TNBC using DBM in women with TNBC.
View Article and Find Full Text PDFThe Activation of p300 Enhances the Sensitivity of Pituitary Adenomas to Dopamine Agonist Treatment by Regulating the Transcription of DRD2.
Int J Mol Sci
November 2024
Sino-German Neuro-Oncology Molecular Laboratory, Department of Neurosurgery, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Jiefang Avenue 1095, Wuhan 430030, China.
Prolactinomas are commonly treated with dopamine receptor agonists (DAs), such as bromocriptine (BRC) and cabergoline (CAB). However, 10-30% of patients exhibit resistance to DA therapies. DA resistance is largely associated with reduced dopamine D2 receptor (DRD2) expression, potentially regulated by epigenetic modifications, though the underlying mechanisms are still unclear.
View Article and Find Full Text PDFDoes hyperprolactinemia treatment affect pregnancy and perinatal outcomes?
Rev Assoc Med Bras (1992)
November 2024
University of Campinas, School of Medicine - Campinas (SP), Brazil.
Objective: The aim of this study was to assess obstetric and perinatal outcomes in women with hyperprolactinemia according to the type of treatment indicated, with cabergoline or bromocriptine.
Methods: A retrospective cohort study with 464 women diagnosed with hyperprolactinemia was undertaken at the endocrine gynecology outpatient clinic of a tertiary hospital from May 2002 to February 2022. All women diagnosed with hyperprolactinemia who were being treated with dopamine agonists (cabergoline or bromocriptine) and who became pregnant during the follow-up were included.
The effectiveness and safety of aripiprazole, bromocriptine, and cabergoline in the treatment of hyperprolactinemia: a systematic review and network meta-analysis.
Expert Opin Drug Saf
October 2024
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Article Synopsis
- The study aimed to evaluate how effective and safe aripiprazole, bromocriptine, and cabergoline are for treating hyperprolactinemia through a network meta-analysis of randomized controlled trials (RCTs).
- A total of 44 RCTs with 3,886 patients were analyzed, revealing that cabergoline combined with conventional therapy was most effective in lowering prolactin levels, especially in non-drug-induced cases.
- The findings suggested that different dopamine receptor agonists have specific advantages: cabergoline for non-drug-induced cases, aripiprazole for cases induced by antipsychotics or antidepressants, and bromocriptine for improving estrogen levels.
Drug induced hypoprolactinemia.
Rev Endocr Metab Disord
December 2024
Faculty of Medicine, Department of Endocrinology, Yeditepe University, İstanbul, Türkiye.
Prolactin levels can be influenced by multiple medications primarily through the interaction with dopamine receptors which regulate its secretion. Unlike hyperprolactinemia which has a well-defined clinical phenotype, the effects of hypoprolactinemia beyond inability to lactate are incompletely understood. Recent studies have raised concerns regarding detrimental changes in glucose metabolism, sexual function and psychological profile in patients with low prolactin levels.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!